Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 170

1.

Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer.

Keating NL, O'Malley AJ, Smith MR.

J Clin Oncol. 2006 Sep 20;24(27):4448-56.

PMID:
16983113
2.

Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer.

Keating NL, O'Malley AJ, Freedland SJ, Smith MR.

J Natl Cancer Inst. 2010 Jan 6;102(1):39-46. doi: 10.1093/jnci/djp404. Epub 2009 Dec 7. Erratum in: J Natl Cancer Inst. 2012 Oct 3;104(19):1518-23.

3.

Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer.

Keating NL, O'Malley A, Freedland SJ, Smith MR.

J Natl Cancer Inst. 2012 Oct 3;104(19):1518-23. No abstract available.

4.

Androgen-deprivation therapy for nonmetastatic prostate cancer is associated with an increased risk of peripheral arterial disease and venous thromboembolism.

Hu JC, Williams SB, O'Malley AJ, Smith MR, Nguyen PL, Keating NL.

Eur Urol. 2012 Jun;61(6):1119-28. doi: 10.1016/j.eururo.2012.01.045. Epub 2012 Feb 1.

5.

Comparison of Gonadotropin-Releasing Hormone Agonists and Orchiectomy: Effects of Androgen-Deprivation Therapy.

Sun M, Choueiri TK, Hamnvik OP, Preston MA, De Velasco G, Jiang W, Loeb S, Nguyen PL, Trinh QD.

JAMA Oncol. 2016 Apr;2(4):500-7. doi: 10.1001/jamaoncol.2015.4917.

PMID:
26720632
6.

Does comorbidity influence the risk of myocardial infarction or diabetes during androgen-deprivation therapy for prostate cancer?

Keating NL, O'Malley AJ, Freedland SJ, Smith MR.

Eur Urol. 2013 Jul;64(1):159-66. doi: 10.1016/j.eururo.2012.04.035. Epub 2012 Apr 19.

7.

The impact of androgen-deprivation therapy (ADT) on the risk of cardiovascular (CV) events in patients with non-metastatic prostate cancer: a population-based study.

Gandaglia G, Sun M, Popa I, Schiffmann J, Abdollah F, Trinh QD, Saad F, Graefen M, Briganti A, Montorsi F, Karakiewicz PI.

BJU Int. 2014 Dec;114(6b):E82-9. doi: 10.1111/bju.12732. Epub 2014 Jul 27.

8.

Risk of colorectal cancer in men on long-term androgen deprivation therapy for prostate cancer.

Gillessen S, Templeton A, Marra G, Kuo YF, Valtorta E, Shahinian VB.

J Natl Cancer Inst. 2010 Dec 1;102(23):1760-70. doi: 10.1093/jnci/djq419. Epub 2010 Nov 10.

9.

Risk and timing of cardiovascular disease after androgen-deprivation therapy in men with prostate cancer.

O'Farrell S, Garmo H, Holmberg L, Adolfsson J, Stattin P, Van Hemelrijck M.

J Clin Oncol. 2015 Apr 10;33(11):1243-51. doi: 10.1200/JCO.2014.59.1792. Epub 2015 Mar 2.

PMID:
25732167
10.

Androgen-deprivation therapy and risk for biliary disease in men with prostate cancer.

Saylor PJ, Smith MR, O'Malley AJ, Keating NL.

Eur Urol. 2014 Mar;65(3):642-9. doi: 10.1016/j.eururo.2013.02.003. Epub 2013 Feb 12.

11.

Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality.

Tsai HK, D'Amico AV, Sadetsky N, Chen MH, Carroll PR.

J Natl Cancer Inst. 2007 Oct 17;99(20):1516-24. Epub 2007 Oct 9.

PMID:
17925537
12.

Androgen-deprivation therapy in treatment of prostate cancer and risk of myocardial infarction and stroke: a nationwide Danish population-based cohort study.

Jespersen CG, Nørgaard M, Borre M.

Eur Urol. 2014 Apr;65(4):704-9. doi: 10.1016/j.eururo.2013.02.002. Epub 2013 Feb 12.

PMID:
23433805
13.

The cardiovascular risk of gonadotropin releasing hormone agonists in men with prostate cancer: an unresolved controversy.

Conteduca V, Di Lorenzo G, Tartarone A, Aieta M.

Crit Rev Oncol Hematol. 2013 Apr;86(1):42-51. doi: 10.1016/j.critrevonc.2012.09.008. Epub 2012 Oct 23. Review.

PMID:
23092636
14.

Androgen deprivation increases the risk of fracture in prostate cancer patients: a population-based study in Chinese patients.

Wu CT, Yang YH, Chen PC, Chen MF, Chen WC.

Osteoporos Int. 2015 Sep;26(9):2281-90. doi: 10.1007/s00198-015-3135-9. Epub 2015 May 20.

PMID:
25990353
15.

Endocrine treatment of prostate cancer.

Tammela T.

J Steroid Biochem Mol Biol. 2004 Nov;92(4):287-95. Epub 2004 Dec 31. Review.

PMID:
15663992
16.

Relationship between androgen deprivation therapy and community-acquired respiratory infections in patients with prostate cancer.

Schmid M, Hanske J, Ravi P, Krishna N, Reznor G, Meyer CP, Fisch M, Noldus J, Nguyen PL, Trinh QD.

Int J Urol. 2016 Apr;23(4):305-11. doi: 10.1111/iju.13043. Epub 2016 Jan 13.

17.

Gonadotropin-releasing hormone agonists and acute kidney injury in patients with prostate cancer.

Gandaglia G, Sun M, Hu JC, Novara G, Choueiri TK, Nguyen PL, Schiffmann J, Graefen M, Shariat SF, Abdollah F, Briganti A, Montorsi F, Trinh QD, Karakiewicz PI.

Eur Urol. 2014 Dec;66(6):1125-32. doi: 10.1016/j.eururo.2014.01.026. Epub 2014 Jan 28.

PMID:
24495466
18.

Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer.

Saigal CS, Gore JL, Krupski TL, Hanley J, Schonlau M, Litwin MS; Urologic Diseases in America Project..

Cancer. 2007 Oct 1;110(7):1493-500.

19.

Cardiovascular Mortality Following Short-term Androgen Deprivation in Clinically Localized Prostate Cancer: An Analysis of RTOG 94-08.

Voog JC, Paulus R, Shipley WU, Smith MR, McGowan DG, Jones CU, Bahary JP, Zeitzer KL, Souhami L, Leibenhaut MH, Rotman M, Husain SM, Gore E, Raben A, Chafe S, Sandler HM, Efstathiou JA.

Eur Urol. 2016 Feb;69(2):204-10. doi: 10.1016/j.eururo.2015.08.027. Epub 2015 Sep 9.

20.

Incidence of fractures causing hospitalisation in prostate cancer patients: results from the population-based PCBaSe Sweden.

Thorstenson A, Bratt O, Akre O, Hellborg H, Holmberg L, Lambe M, Bill-Axelson A, Stattin P, Adolfsson J.

Eur J Cancer. 2012 Jul;48(11):1672-81. doi: 10.1016/j.ejca.2012.01.035. Epub 2012 Mar 3.

PMID:
22386317

Supplemental Content

Support Center